We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bluebird (BLUE) Down 7.8% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for Bluebird Bio (BLUE - Free Report) . Shares have lost about 7.8% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Bluebird due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
bluebird Q2 Earnings and Revenues Beat
bluebird reported a loss of 36 cents per share in second-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of $1.91and the year-ago quarter's loss of $3.55.
Revenues of $198.9 million easily beat the Zacks Consensus Estimate of $102 million. The figure was up from $13.3 million in the year-ago quarter.
Quarter in Detail
R&D expenses increased to $156.3 million from $146.5 million a year ago due to costs incurred by the company to advance and expand the pipeline.
Selling, general and administrative (SG&A) expenses of $68.6 million were almost flat from the year-ago quarter to support its operations, overall growth of the pipeline, and commercial-readiness activities.
Pipeline Development
On July 29, 2020, bluebird bio and Bristol Myers Squibbannounced the submission of their biologics license application (BLA) to FDA for idecabtagene vicleucel (ide-cel; bb2121), the companies’ investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy. This submission provides further details on the Chemistry, Manufacturing and Controls (CMC) module to address the outstanding regulatory requests from the FDA in May 2020 following the original BLA submission.
On May 22, 2020, Bristol Myersannounced that the European Medicines Agency (EMA) validated its marketing authorization applications (MAA) for ide-cel. Validation of the application confirms the submission is complete and begins the EMA’s centralized review process.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. The consensus estimate has shifted 10.19% due to these changes.
VGM Scores
Currently, Bluebird has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Bluebird has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bluebird (BLUE) Down 7.8% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Bluebird Bio (BLUE - Free Report) . Shares have lost about 7.8% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Bluebird due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
bluebird Q2 Earnings and Revenues Beat
bluebird reported a loss of 36 cents per share in second-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of $1.91and the year-ago quarter's loss of $3.55.
Revenues of $198.9 million easily beat the Zacks Consensus Estimate of $102 million. The figure was up from $13.3 million in the year-ago quarter.
Quarter in Detail
R&D expenses increased to $156.3 million from $146.5 million a year ago due to costs incurred by the company to advance and expand the pipeline.
Selling, general and administrative (SG&A) expenses of $68.6 million were almost flat from the year-ago quarter to support its operations, overall growth of the pipeline, and commercial-readiness activities.
Pipeline Development
On July 29, 2020, bluebird bio and Bristol Myers Squibbannounced the submission of their biologics license application (BLA) to FDA for idecabtagene vicleucel (ide-cel; bb2121), the companies’ investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy. This submission provides further details on the Chemistry, Manufacturing and Controls (CMC) module to address the outstanding regulatory requests from the FDA in May 2020 following the original BLA submission.
On May 22, 2020, Bristol Myersannounced that the European Medicines Agency (EMA) validated its marketing authorization applications (MAA) for ide-cel. Validation of the application confirms the submission is complete and begins the EMA’s centralized review process.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. The consensus estimate has shifted 10.19% due to these changes.
VGM Scores
Currently, Bluebird has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Bluebird has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.